Objective: Trans-catheter aortic valve implantation (TAVI) is an alternative for patients not eligible for surgical aortic valve replacement. When peripheral access is not amenable by the transfemoral route (TF-TAVI), the most-used approaches are the trans-apical (TAp-TAVI) and the trans-axillary (TAx-TAVI). The aim of this study is to report the outcomes in a single-center series of consecutive patients treated by TAVI using the different approaches. Methods: From
1. Introduction
Objectives
Degenerative aortic stenosis (AS) is the most common valvular disease requiring hospitalization in the Western countries, with a prevalence of 4.6% in adults over 75 years of age [1] . Accordingly, the need for aortic valve replacement (AVR) will escalate, according to the increase in life expectancy. Surgical AVR remains the standard treatment for patients with severe symptomatic AS, providing relief of symptoms, as well as improving survival and quality of life (QoL) [2, 3] . Nevertheless, up to 30% of patients with severe AS are denied surgery because of advanced age or high surgical risk [4] . Trans-catheter aortic valve implantation (TAVI) provides a reasonable therapeutic option for these patients [5] [6] [7] [8] [9] [10] [11] .
The most-used approach for TAVI is the transfemoral (TF) retrograde route because it is minimally invasive and it is feasible under conscious sedation in a totally percutaneous fashion. When peripheral access is not amenable for the TF approach, different routes have been used, including the trans-apical (TAp) and the trans-axillary (TAx) approaches.
The aim of this study is to report the short-and mid-term outcomes in a consecutive series of patients treated by TAVI using the three different approaches in our Institution.
Methods

Patients
From November 2007 to June 2010, clinical and procedural data from all patients treated with TAVI at our www.elsevier.com/locate/ejcts European Journal of Cardio-thoracic Surgery 40 (2011) 49-55 § Presented at the 24th Annual Meeting of the European Association for Cardio-thoracic Surgery, Geneva, Switzerland, September 11-15, 2010. Institution were entered into a dedicated database. All the patients included in this study presented the criteria for intervention of the European Society of Cardiology (ESC) guidelines for the management of valvular heart disease [3] . The indications for the procedure, according to the European Association of Cardio-Thoracic Surgery/European Society of Cardiology (EACTS/ESC) consensus position statement for TAVI procedures [5] , were: severe symptomatic AS, aortic valve annulus diameter from 19 mm to 27 mm and contraindication to conventional surgery because of co-morbidities or anatomical/technical issues (such as porcelain aorta, prior thoracotomies with patent LIMA grafts, and previous chest irradiation). Informed written consent was obtained from all the patients.
All patients were evaluated by a dedicated multidisciplinary valve team (including surgeons, interventional cardiologists, anesthesiologists, radiologists, and echocardiographists). The individual selection of treatment (TAVI vs surgical AVR) was based on a multimodal decision-making process, including evaluation of surgical risk by EuroSCORE (European System for Cardiac Operative Risk Evaluation) (http://www.euroscore.org/) and Society of Thoracic Surgeons (STS) algorithm (http://209.220.160.181/STSWebRiskCalc261/) as well as adjunctive risk evaluation, such as the presence of advanced liver cirrhosis, severe neurological impairment and frailty. Patient functional status was also assessed with additional tests including Mini Nutritional Assessment (MNA) [12] , Charlson Comorbidity Index (CCI) [13] , and 6-min walk test (6-MWT) [14] . The QoL of the patients was quantified by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) [15] , and by the Short-Form Health Survey 36-Item (SF-36v2 W ) [16] . Preprocedural assessment included transthoracic echocardiography (TTE), carotid ultrasonography, spirometry and evaluation of the peripheral access sites, aortic anatomy, valve annulus size and coronary anatomy by computed tomography (CT) angiography, and/or arterial angiography. Following the instrumental screening, first, the type of prosthesis was chosen depending on the aortic annulus size (Sapien or CoreValve). Consequentially, the best access site to perform the procedure was collegially decided: the TF approach was considered the first choice; if the vascular anatomy was not amenable for the TF approach because of tortuosity of heavy calcifications, the TAx) or the TAp route was considered.
All the patients included in the study were followed up in our dedicated outpatient clinic by means of clinical examination and TTE at 30 days, 6 months and 12 months; follow-up was 100% complete.
Procedure
Two devices have been used: the SAPIEN (and, more recently, the SAPIEN XT) valve (Edwards Lifescience Inc., CA, USA) [9] and the third-generation CoreValve Revalving System (Medtronic Inc., MN, USA) [7] . The comprehensive descriptions of the procedures are reported elsewhere [7, 17] . Briefly, retrograde TF procedures were performed in the catheterization laboratory, under fluoroscopic guidance. General anesthesia or deep sedation was employed, according to the anesthesiologist's judgment. The TF approach was managed with preclosure using two 10 Fr Prostar closure devices (Abbott Vascular, Abbott Park, IL, USA) in all patients.
In patients with small or diseased iliofemoral arteries, TAVI was performed by the TAx approach via surgical isolation and direct puncture of the left axillary artery, under local anesthesia, in most patients. For the Tax approach, the CoreValve system was used more frequently.
In cases of unsuitable subclavial access, the TAp approach through a left minithoracotomy was used, according to the conventional technique [18] . All the TAp procedures were performed in the operative room under general anesthesia.
After the procedure, the patients were transferred to the intensive care unit (ICU) and monitored. Before the discharge, TTE, electrocardiography (ECG), and chest Xray were routinely performed in all patients.
Statistical analysis
Statistical analysis has been conducted using the JMP 8.0 software (SAS Institute Inc, NC, USA). Continuous variables are presented as mean AE SD and categorical variables are expressed as percentages. Univariable comparisons have been performed with analysis of variance (ANOVA) for normally distributed data. The Kruskal-Wallis test was used for comparisons of non-parametric continuous data and the chi-square test for categorical data. Survival has been reported using the Kaplan-Meier method and the log-rank method was used for comparison. A p-value < 0.05 was considered statistically significant, and all reported p-values are two-sided.
Univariate analysis of predictor of 6 months' death was performed with Cox proportional hazard regression. Variables with a p-value < 0.1 were entered in a multivariable model.
Results
Baseline characteristics
A total of 177 consecutive patients with symptomatic, severe AS underwent TAVI in our Institution. The TF approach was used in 140 patients (79.1%), the TAx approach in 19 patients (10.7%), and the TAp approach in 16 (9.1%). One patient intended to be treated by the TAx approach was converted to the TF approach during the procedure. Two patients (1.1%) with 'no-access options' underwent the transaortic approach and were not included in this study. An Edwards-SAPIEN prosthesis was implanted in 97 (55.4%) patients (78 TF, 16 TAp and three TAx approaches). In seven cases (7.2%) a valve-in-valve implantation to treat a previously implanted degenerated bioprosthesis was performed; a CoreValve prosthesis was implanted in 78 (44.6%) patients (62 TF and 16 TAx approaches).
Baseline clinical features of the study population are summarized in Table 1 . The three groups were not different in terms of age ( p = 0.6), left ventricular ejection fraction (LVEF) ( p = 0.6), Log-EuroSCORE ( p = 0.3), STS score ( p = 0.7), and New York Heart Association (NYHA) functional class ( p = 0.7), while the incidence of peripheral vascular disease ( p < 0.0001), porcelain aorta ( p < 0.0001), and cerebrovascular disease ( p = 0.003) was higher in the TAp group. The prevalence of respiratory failure (defined as forced expiratory volume in 1 s/forced vital capacity (FEV 1 / FVC) < 0.7) was almost double in patients undergoing TAx, although the difference did not reach statistical significance.
The CCI was 5.9 AE 1.8, 8.7 AE 4.9, and 5.8 AE 1.2 for TF, TAp, and TAx, respectively ( p = 0.02), indicating that patients of the TAp group had the most significant burden of co-morbidities. QoL indices revealed an important impairment in terms of perceived QoL in all patients, without any difference among the groups (MLHFQ was 42 AE 15.1, 42.0 AE 17.5, and 53.1 AE 16.7 for TF, TAp, and TAx, respectively -p = 0.2-; SF-36 physical domain was 31.7 AE 9.6, 29.4 AE 6.6, and 30.7 AE 9.9 for TF, TAp, and TAx, respectively -p = 0.7-), such as 6-MWT performances (156.5 AE 18.6 m, 160.0 AE 53.5 m, and 230 AE 160.1 m for TF, TAp, and Tax, respectively; -p = 0.7). Table 2 summarizes the periprocedural results. Procedural success (successful implantation of the device without intraprocedural mortality or need to conversion to open-heart surgery) was 98.8%. One patient of the TF group was converted to conventional surgery due to acute type A aortic dissection. One patient of the TAx group, intended to be treated with the SAPIEN XT system, after balloon predilatation had massive acute aortic regurgitation; unfortunately, valve implant was impeded by kinking of the sheath; therefore, emergent TF implantation with CoreValve was done, and was performed successfully. However, left ventricular function did not recover and extracorporeal membrane oxygenation (ECMO) support was initiated; the patients left the lab alive but died within 24 h of support.
Procedural and 30-day outcomes
In-hospital (30 day) mortality was 1.4% (2/140), 12.5% (2/ 16), and 5.3% (1/19) for TF, TAp, and TAx, respectively ( p = 0.03). One patient of the TF group died because of hemorrhagic shock due to retroperitoneal bleeding 1 day after the procedure and the other died because of cardiogenic shock and multi-organ failure in the ICU 10 days after the procedure; one patient of the TAp group died 3 days after the intervention because of unresponsive arrhythmic storm; the second intrahospital death in the TAp group occurred 5 days after the procedure because of sudden death (probably related to transient asystolia followed by arrhythmias). In both cases, normal prosthesis function was determined before death, but both had moderate-to-severe perivalvular regurgitation that was accepted at the end of the procedure because of the hemodynamic stability of the patients; one patients of the TAx group has been described above.
The incidence of major adverse cardiac and cerebrovascular events (MACCEs) at 30 days was 12.1% (17/140 patients), 18.0% (3/16 patients), and 15.7% (3/19 patients) for TF, TAp, and TAx, respectively ( p = 0.6). The incidence of major vascular complications in the TF group (defined as any vascular injury requiring non-planned additional percutaneous or surgical treatment) was 17.2% (24/140 patients).
The incidence of new-onset heart block requiring permanent pacemaker was 13.6% in the TF approach (19 patients), 18.7% in the TAp approach (three patients), and 5.2% in the TAx approach (one patient) (-p = 0.5). Neurologic events occurred in 2.2% of the patients of the TF group (two transient ischemic attacks and one stroke, all within 24 h from the procedure); one transient ischemic attack occurred in the TAx group.
Incidence of acute renal failure requiring renal ultrafiltration was 4.3% (6/140 patients), 25% (4/16 patients), and 10.9% (2/19 patients) in TF, TAp, and TAx groups, respectively ( p = 0.06).
No periprocedural acute myocardial infarction was observed. In one TAp patient, uneventful right coronary artery occlusion occurred, without any clinical or hemodynamic consequence.
Postprocedural, mild, paravalvular regurgitation was a recurrent finding (trivial or mild: 72%, moderate: 4%; and severe: 1.5%), with no differences among the three groups.
Mean length of stay was 9.3 AE 12.5 days (median 6 days) for the TF group, 14.8 AE 18.3 days (median 6 days) for the TAp group, and 8.5 AE 3.5 days (median 7 days) for the TAx group ( p = 0.2).
Follow-up
Follow-up was 100% complete (mean 6.0 AE 6.8 months). Actuarial survival at 6 months was 88.4 AE 3.1% for the TF group, 72.2 AE 12.0% for the TAp group, and 67.4 AE 17.4% for the TAx group ( p = 0.3) (Fig. 1) .
Cumulative cardiovascular death occurred in 7.1% of the TF group (10 patients: three patients died from sudden death, one from stroke, one from acute pulmonary edema, one from cardiogenic shock in the ICU, and four from major bleeding), in 25% of the patients of the TAp group (four patients: two from ventricular arrhythmia, one from acute myocardial infarction, and one from postprocedural intraventricular septal defect), and in 10.5% of the patients of the TAx group (one patient died in the ICU from cardiogenic shock after resuscitation; and one patient with moderate residual paravalvular leak died from acute pulmonary edema and superimposed respiratory infection) ( p = 0.06).
At last follow-up, 93.4% of the patients of the TF group, 91.7% of the TAp group, and 81.3% of the TAx group was in NYHA functional class I or II ( p = 0.3).
Univariate analysis indicated LVEF, Logistic EuroSCORE, preprocedural renal failure, and periprocedural acute renal failure requiring ultrafiltration predictors of 6 months death (Table 3) .
At multivariate analysis, LVEF and periprocedural acute renal failure requiring ultrafiltration resulted as the major predictors of death at 6 months (Table 4) .
At last follow-up, mean SF-36-physical improved from 30.5 AE 8.6 to 51.4 AE 6.7 ( p < 0.0001) and SF-36-mental improved from 44.9 AE 11.6 to 50.3 AE 2.5 ( p = 0.0002). Mean MLHFQ decreased from 43.8 AE 12.7 to 14.9 AE 15.4 ( p < 0.0001). 
Discussion
In a consecutive series of patients undergoing TAVI in a single institution, a variety of approaches have been used to accommodate the anatomical and clinical variabililties observed among the patients. The TF approach has been considered the first choice due to its reduced invasiveness and the feasibility of the procedure under local anesthesia, factors believed to be beneficial in a high-risk population. In approximately 20% of patients, an alternative approach has been used, equally distributed between the TAp and the TAx approaches. In our experience, one of the most important issues that can explain the excellent results of the TF approach is likely the use of the TF approach as a first choice every time it seems safely feasible, in the presence of optimal access. The availability of alternative approaches, in fact, as the Tax and the Tap, allows us to avoid forcing the indication of a TF approach in patients with suboptimal peripheral access and that might end in a better TF outcome.
Although our series is limited in size, the TAx approach demonstrated lower hospital mortality and length of stay than the TAp, regardless of the fact that clinical characteristics of the groups were similar, with a high incidence of peripheral vascular disease. However, at longer term, no significant differences between the two groups were observed.
The lower in-hospital morbidity observed in patients undergoing the TAx approach was probably related to multiple factors. Compared with TAp, local anesthesia and reduced invasiveness allowed faster recovery with reduced need for intensive care. The short route to the aortic valve as well as the surgical isolation of the axillary artery allowed precise implant while minimizing vascular access complications. The only patient who died in the TAx group had a device-related issue, unknown before the implant. It must be noted that axillary access is an off-label route of implant. More specifically, the unfortunate case we described suggests that the Sapien XT system is not ideal for the axillary approach. Therefore, we still continue to use the axillary approach, but exclusively with the CoreValve system.
The 6 months' results of the TAp and TAx approaches were most probably related to the similar initial selection bias, with high prevalence of peripheral vascular disease. This was associated with chronic respiratory disease in most patients undergoing the axillary approach.
TAVI is a therapeutic modality alternative to surgical AVR for the treatment of degenerative severe AS for patients at high surgical risk due to elderly, heavy comorbidities or technical issues. Since its first report in 2002 by Cribier [19] , thousands of patients have been successfully submitted to TAVI worldwide and, nowadays, TAVI has emerged as a safe and effective procedure for inoperable patients with both the available devices (Edwards SAPIEN and CoreValve).
The most-used approach for TAVI is currently the retrograde TF approach through the common femoral artery because of its noninvasiveness with a fully percutaneous technique in most cases.
However, the TF approach is contraindicated in many patients with peripheral artery disease in which ileofemoral access is not amenable for this type of procedure because of excessive atherosclerosis, calcifications, or tortuosity.
To treat patients, who are not suitable for the TF approach, the trans-apical and trans-axillary routes have been proposed as alternatives, both with satisfactory results.
The SOURCE Registry (SAPIEN aortic bioprosthesis European Outcome), which was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecutive high-risk patients in Europe, reported a 30-day mortality of 10.3% in TAp patients [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Similarly, the recently published Canadian experience with the SAPIEN valve reported an overall 30-day mortality of 10.4% (9.5% for the TF approach and 11.3% for the TAp approach) and a mortality rate of 22.1% at a mean follow-up of 8 months [11] . Walther et al. reported very satisfactory results with the TAp approach in high-risk patients (90% of 30-day survival and 73% of 1-year survival) [21] .
The results of the TAx approach are also promising. Recently, a multicentric Italian study [22] reported, in 54 consecutive patients treated by the TAx approach with the CoreValve, a 30-day mortality of 0%, while Modine et al. reported a 30-day mortality of 11% for this approach [23] .
In spite of the ongoing diffusion of these two approaches due to an increasing complexity of the patients to be treated, no direct comparisons of the TAp and TAx approaches have been reported.
In our experience, 30-day mortality was very low with the TF and TAx approaches (1.4% and 5.3%, respectively), while the 30-day mortality of the TAp approach (12.5%) was similar to the ones reported in the SOURCE registry and in the Canadian experience. Similarly, despite comparable inhospital length of stay, the incidence of complications, such as acute renal failure requiring ultrafiltration, was higher in the TAp group. This may be a consequence of a selection bias due to a more important burden of extracardiac comorbidities in patients who are not eligible for the TF or TAx approach, as suggested by the higher CCI and by the higher surgical risk scores of the TAp group, indicating that patients candidate to TAp implantation are a different and more compromised population. However, the TAx group shares with the TAp the same selection bias related to the high incidence of peripheral vascular disease, as these approaches were only considered when the femoral approach was not feasible. Nevertheless, being less invasive and requiring local anesthesia, the TAx approach seems to be a valid therapeutic alternative to the TAp approach in patients who are not eligible for TF.
At 6 months follow-up, the outcomes of the patients treated by the TF approach are very satisfactory. It is interesting to note that at 6 months' follow-up, survival and complications rate of the TAp and TAp approaches become similar, mostly due to the extracardiac copathologies.
These results confirm the fact that patients who are ineligible for TF-TAVI and who underwent TAx and TAp implantation may suffer from a similar selection bias. It is important to underline that conventional surgical risk score may be inadequate to predict the outcomes of such a population of patients, suggesting that specific risk scores for TAVI would be needed.
Limitations of the study
This study was a single-center study; therefore, the size was small to make strong conclusions. The groups were not randomized into the different treatment arms, and results include the initial learning curve with the different approaches. Moreover, the three groups of this study are not numerically homogeneous, and the TAx and TAp groups are too small to be compared with the TF group. Randomized selected groups would be required in a prospective study to compare the different approaches.
Conclusions
In spite of some adjunctive specific contraindications (respiratory failure and previous left ventricular restoration surgery) and of more invasive techniques requiring general anesthesia, TAp-TAVI remains generally the first alternative for patients with suboptimal vascular access. The TAx approach is less invasive and offers some advantages over the TAp approach, avoiding general anesthesia and need for intensive care. In our experience, the TAx approach has become the second choice after TF and before TAp in the selection of approach for TAVI.
In conclusion, we can state that the availability and the use of wide options (three alternative approaches and two different devices) to treat such different types of patients allow to personalize the treatment, decreasing procedural risks and improving outcomes.
Larger and randomized studies are needed to directly compare the two approaches alternative to TF.
